3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
223
Carboplatin
218
Cisplatin
205
Paclitaxel
182
Gemcitabine
149
Docetaxel
127
Capecitabine
114
Dexamethasone
102
Pemetrexed
101
Cyclophosphamide
101
Specimen Handling
99
Magnetic Resonance Spectroscopy
97
Oxaliplatin
96
Radiotherapy
95
Doxorubicin
91
Fluorouracil
87
Bevacizumab
83
Nivolumab
74
Leucovorin
72
Rituximab
70
Vincristine
67
durvalumab
66
Lenalidomide
63
Etoposide
62
atezolizumab
61
Radiation
61
Irinotecan
60
130-nm albumin-bound paclitaxel
57
Prednisone
56
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Histamine H2 Antagonists
×
1 year
×
Clear all
NCT06305754
2026-05-29
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
520 enrolled
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled